AxoGen, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue to be in the range of $177 million to $181 million, which represents an annual growth rate of approximately 11% to 14%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 USD | -0.99% | +2.05% | +2.05% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.05% | 305M | |
+9.48% | 222B | |
+13.72% | 195B | |
+23.79% | 148B | |
+33.39% | 113B | |
+4.75% | 66.45B | |
+3.16% | 50.03B | |
-4.35% | 38.8B | |
-1.27% | 34.85B | |
+22.61% | 30.98B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024